Suppression by sorted CD8+CD11b− cells from T-cell growth factor-activated peripheral blood lymphocytes on cytolytic activity against tumour in patients with gastric carcinoma

European Journal of Cancer and Clinical Oncology Pub Date : 1991-12-01 DOI:10.1016/0277-5379(91)90439-K

T. Ebihara, N. Sakai, S. Koyama

{"title":"Suppression by sorted CD8+CD11b− cells from T-cell growth factor-activated peripheral blood lymphocytes on cytolytic activity against tumour in patients with gastric carcinoma","authors":"T. Ebihara, N. Sakai, S. Koyama","doi":"10.1016/0277-5379(91)90439-K","DOIUrl":null,"url":null,"abstract":"<div>To confirm the phenotypic characteristics of lymphokine-activated suppressor (LAS)effector cells, we isolated CD8+CD11b− and CD8−CD11b− cells from T-cell growth factor (TCGF)-activated peripheral blood lymphocytes (PBL) in 7 patients with gastric carcinoma (4 non-resectable and 3 resectable carcinoma) and 3 healthy controls. Sorted CD8+CD11b− cells from 3 of the patients with non-resectable carcinoma and from 1 of the patients with resectable carcinoma showed LAS cell activity. However, the LAS cell activity could not be observed in CD8+CD11b− cells from healthy controls. In addition, a sorted CD8−CD11b− subset of cells from both cancer patients and control did not express any suppressive activity. These facts clearly show that the cell populations responsible for suppression of cell-mediated antitumour immunity reside within CD8+CD11b− T-cells, at least in patients with advanced carcinoma.</div>","PeriodicalId":11925,"journal":{"name":"European Journal of Cancer and Clinical Oncology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"1991-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0277-5379(91)90439-K","citationCount":"8","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Cancer and Clinical Oncology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/027753799190439K","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 8

Abstract

To confirm the phenotypic characteristics of lymphokine-activated suppressor (LAS)effector cells, we isolated CD8⁺CD11b⁻ and CD8⁻CD11b⁻ cells from T-cell growth factor (TCGF)-activated peripheral blood lymphocytes (PBL) in 7 patients with gastric carcinoma (4 non-resectable and 3 resectable carcinoma) and 3 healthy controls. Sorted CD8⁺CD11b⁻ cells from 3 of the patients with non-resectable carcinoma and from 1 of the patients with resectable carcinoma showed LAS cell activity. However, the LAS cell activity could not be observed in CD8⁺CD11b⁻ cells from healthy controls. In addition, a sorted CD8⁻CD11b⁻ subset of cells from both cancer patients and control did not express any suppressive activity. These facts clearly show that the cell populations responsible for suppression of cell-mediated antitumour immunity reside within CD8⁺CD11b⁻ T-cells, at least in patients with advanced carcinoma.

查看原文本刊更多论文

t细胞生长因子活化的外周血淋巴细胞中CD8+CD11b−细胞对胃癌患者抗肿瘤活性的抑制作用

为了证实淋巴因子激活抑制(LAS)效应细胞的表型特征，我们从7例胃癌患者(4例不可切除癌和3例可切除癌)和3例健康对照的t细胞生长因子(TCGF)激活的外周血淋巴细胞(PBL)中分离出CD8+CD11b -和CD8 - CD11b -细胞。3例不可切除癌患者和1例可切除癌患者的CD8+CD11b−细胞均显示LAS细胞活性。然而，在健康对照的CD8+CD11b−细胞中未观察到LAS细胞活性。此外，来自癌症患者和对照组的CD8 - CD11b -细胞亚群均未表达任何抑制活性。这些事实清楚地表明，至少在晚期癌症患者中，负责抑制细胞介导的抗肿瘤免疫的细胞群存在于CD8+CD11b−t细胞中。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European Journal of Cancer and Clinical Oncology

自引率

0.00%

发文量